Sarah Rockwell, PharmD, BCOP

Malignant Hematology🩸PharmD @moffittnews || @uf alum x 2 🐊

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

[THREAD] CNS Prophylaxis in DLBCL Thread (selected references; work in progress) [Updated Dec 9, 2020] #lymsm #btsm cc @scmedlin @tobyeyre82 @graham74GC @DrDanPersky @GregNowakowski @Lymphoma_Doc @ChrisRFlowersMD @timfenske @AndreGoyMD @drcthompson @Lymphoma_MD @chanyooncheah

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

Excited and honored to share our work at #ASH20 @JulioChavezMD Check out our abstract to see if #EPOCH is better than #RCHOP in high risk DLBCL #lymsm #TwitteRX thank you @MoffittNews !

[Moffitt Cancer Center @MoffittNews]

Dr. Rockwell (@rockwell_pharmD) of @MoffittNews presents Moffitt study retrospectively comparing DA-EPOCH-R to R-CHOP in the treatment of high-risk DLBCL at #ASH20. View abstract- https://t.co/LKcHcniFGU

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

Exciting ZUMA-12 results thus far @JulioChavezMD

[The Lancet Haematology @TheLancetHaem]

Axicabtagene ciloleucel as first-line therapy in patients with high-risk large B-cell lymphoma: interim analysis of ZUMA-12 showing promising response data #ASH #lymsm

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

Very important data set presented by Dr Orellana-Noia on lack of benefit of CNS prophylaxis with *EITHER* IV or IT methotrexate. Thought provoking, unclear if we should abandon prophylaxis in high risk patients yet tho. Eagerly anticipating the manuscript. #ASH20

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

“Some degree of immunity is better than no degree of immunity” Dr. Fauci on vaccinating our immunocompromised patients with the #COVID19 vaccine #ASH20

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

Incredible fireside chat with Dr. Fauci this morning at #ASH20. #legend #scienceis👑

[Ahmar U. Zaidi, MD (Dr. Z) @drzsicklecell]

Fireside with Fauci #ASH20: a thread. #ASH20 /1

[Hayder Saeed, MD @HayderSaeed_MD]

#CART in #CLL Richter transformation in #ASH20 from Dr. Weirda #lymsm #leusm

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

Congrats on one of your many abstracts at #ASH20 @JulioChavezMD 👏🏻 all great work!

[Moffitt Cancer Center @MoffittNews]

Dr. Chavez presents phase 1 data on the use of the ICOS monoclonal antibody MEDI-570 for relapsed/refractory lymphomas at #ASH20. View abstract- https://t.co/pNEfO20eGX

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

Excellent work Dr. Yun and team 👏🏻 #ASH20

[Moffitt Cancer Center @MoffittNews]

Moffitt study supports using SL-401 or hyper-CVAD as a first-line treatment for blastic plasmacytoid dendritic cell neoplasm, a rare hematologic malignancy. #ASH20 View abstract- https://t.co/ZYgSxXGZ89

[Sarah Rockwell, PharmD, BCOP @rockwell_pharmd]

@JulioChavezMD I agree - the toxicities are certainly greater for limited to no benefit in DLBCL and subsets based on what we have seen in most of our high-risk patients. Could R-CHOP be the new face of “less is more”?!